Finch Therapeutics Group Alpha and Beta Analysis
| FNCHDelisted Stock | USD 8.51 0.19 2.18% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Finch Therapeutics Group. It also helps investors analyze the systematic and unsystematic risks associated with investing in Finch Therapeutics over a specified time horizon. Remember, high Finch Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Finch Therapeutics' market risk premium analysis include:
Beta (0.88) | Alpha (0.10) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Finch |
Finch Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Finch Therapeutics market risk premium is the additional return an investor will receive from holding Finch Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Finch Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Finch Therapeutics' performance over market.| α | -0.1 | β | -0.88 |
Finch Therapeutics Fundamentals Vs Peers
Comparing Finch Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Finch Therapeutics' direct or indirect competition across all of the common fundamentals between Finch Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Finch Therapeutics or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Finch Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Finch Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Finch Therapeutics to competition |
| Fundamentals | Finch Therapeutics | Peer Average |
| Return On Equity | -0.63 | -0.31 |
| Return On Asset | -0.22 | -0.14 |
| Current Valuation | 10.74 M | 16.62 B |
| Shares Outstanding | 1.61 M | 571.82 M |
| Shares Owned By Insiders | 53.48 % | 10.09 % |
| Shares Owned By Institutions | 11.35 % | 39.21 % |
| Number Of Shares Shorted | 19.2 K | 4.71 M |
Finch Therapeutics Opportunities
Finch Therapeutics Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Finch Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Finch or other pink sheets. Alpha measures the amount that position in Finch Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Finch Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Finch Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Finch Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Finch Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Finch Therapeutics. Please utilize our Beneish M Score to check the likelihood of Finch Therapeutics' management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Finch Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |